NUPLAZID™
(pimavanserin) tablets

Please see Important Safety Information, including Boxed Warning below.

You are invited to a Presentation on:

Treating the Hallucinations and Delusions Associated with Parkinson's Disease Psychosis

Presented by

Susan Scanland, APRN, CRNP, NP-C, MSN, GNP
Dementia Connection LLC

Date & Location

Wednesday, November 9, 2016
6:00 PM Eastern At
Creeds Restaurant
499 North Gulph Road
King of Prussia, Pennsylvania 19406

Program Objectives

- Understand the symptoms, diagnosis, and impact of the hallucinations and delusions associated with Parkinson's disease psychosis (PDP)
- Explore the proposed mechanism of action of NUPLAZID (pimavanserin)
- Discuss the efficacy, safety, and administration of NUPLAZID for the treatment of hallucinations and delusions associated with PDP

RSVP Information

Please call Duane Arnold at
(201) 388-0067 or email darnold@acadia-pharm.com

Please refer to Meeting ID number: ACA0000803

Important Safety Information and Indication for NUPLAZID™ (pimavanserin) tablets

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. NUPLAZID is not approved for the treatment of patients with dementia-related psychosis unrelated to the hallucinations and delusions associated with Parkinson's disease psychosis.

QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.

Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID and greater than placebo) were peripheral edema (7% vs 2%), nausea (7% vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%), constipation (4% vs 3%), and gait disturbance (2% vs <1%).

Drug Interactions:
Strong CYP3A4 inhibitors (eg, ketoconazole) increase NUPLAZID concentrations. Reduce the NUPLAZID dose by one- half.
Strong CYP3A4 inducers may reduce NUPLAZID exposure, monitor for reduced efficacy. Increase in NUPLAZID dosage may be needed.

Renal Impairment: No dosage adjustment for NUPLAZID is needed in patients with mild to moderate renal impairment. Use of NUPLAZID is not recommended in patients with severe renal impairment.

Hepatic Impairment: Use of NUPLAZID is not recommended in patients with hepatic impairment. NUPLAZID has not been evaluated in this patient population.

Pediatric Use: Safety and efficacy have not been established in pediatric patients.

Dosage and Administration: Recommended dose: 34 mg per day, taken orally as two 17 mg tablets once daily, without titration.

INDICATIONS AND USAGE
NUPLAZID is an atypical antipsychotic indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Please clickto see Full Prescribing Information.

www.NUPLAZID.com

ACADIA Pharmaceuticals is pleased to sponsor this program to provide information consistent with FDA guidelines. This program is not an accredited CME program and is not designed to meet any training and/or educational requirements. In accordance with the PhRMA Code on Interactions with Healthcare Professional, attendance at this educational program is limited to only Healthcare Professionals (Physicians, Nurse Practitioners, Physician Assistants, RNs, Clinical Pharmacists, Social Workers). Accordingly, attendance by guests or spouse is not permitted.

To comply with certain federal, state, and local laws that prohibit or limit the provision of meals to health care professionals and/or state employees, (e.g., Vermont and Minnesota) ACADIA Pharmaceuticals does not offer a complimentary meal to individuals who are subject to such restrictions. Attendees to whom such restrictions apply should not avail themselves of the complimentary meal. The venue will, however, provide an opportunity for the meal to be charged to an attendee's personal account (e.g. credit card). If you are unsure of your state's laws and regulations, we ask that you please check prior to attending this event.

Please note that ACADIA Pharmaceuticals is required to report the value of a provided meal pursuant to applicable federal and/or state laws.

This invitation is non-transferrable.

ACADIA® Pharmaceuticals